Preclinical Science Regarding Cannabinoids as Analgesics: An Overview | Zendy

Maureen E. Lynch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preclinical Science Regarding Cannabinoids as Analgesics: An Overview

Author(s) -

Maureen E. Lynch

Publication year - 2005

Publication title -

pain research and management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.702

H-Index - 56

eISSN - 1918-1523

pISSN - 1203-6765

DOI - 10.1155/2005/169093

Subject(s) - cannabinoid receptor , cannabinoid , synthetic cannabinoids , delta 9 tetrahydrocannabinol , cannabinoid receptor agonists , pharmacology , medicine , chronic pain , cannabis , nociception , effects of cannabis , endocannabinoid system , analgesic , neuroscience , receptor , psychology , cannabidiol , psychiatry , agonist

Modern pharmacology of cannabinoids began in 1964 with the isolation and partial synthesis of delta-9-tetrahydrocannabinol, the main psycho-active agent in herbal cannabis. Since then, potent antinociceptive and antihyperalgesic effects of cannabinoid agonists in animal models of acute and chronic pain; the presence of cannabinoid receptors in pain-processing areas of the brain, spinal cord and periphery; and evidence supporting endogenous modulation of pain systems by cannabinoids has provided support that cannabinoids exhibit significant potential as analgesics. The present article presents an overview of the preclinical science.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research